{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T23:12:13Z","timestamp":1774653133156,"version":"3.50.1"},"reference-count":19,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2016,10,30]]},"abstract":"<jats:p>Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy. Thirty nine PCOS women were randomized into three groups and treated with alfacalcidiol (Group 1), combined alfacalcidiol and metformin therapy (Group 2) and metformin (Group 3) for 6 months. Serum TST, fTST, DHEAS, LH and LH\/FSH were measured before and after six months of treatment. Menstrual cycle regularity, hirsutism, acne and pregnancy rate were assessed at the same time. There was a significant decrease in TST levels in the Group 2 and slight but not significant decrease in the Group 3. No significant changes in other parameters (fTST, DHEAS, LH, LH\/FSH) have been found after 6 months therapy in all three groups. An improvement of menstrual cycle was detected in 78 % of patients in Group 1 (p&lt;0.04), 80 % in the Group 2 (p&lt;0.03) and in 90 % in the Group 3 (p&lt;0.002), respectively. There was no significant improvement of acne and hirsutism in all three groups (all p not significant). Pregnancy rate was higher in the Group 3 as compared with Groups 1 and 2 (67 % vs. 0 % and 25 %, respectively), however without statistical significance. Vitamin D administration has no significant effect on androgen levels and clinical features of hyperandrogenism in obese vitamin D deficient PCOS women. However, it can potentiate effect of metformin on testosterone levels and LH\/FSH ratio but not on clinical hyperandrogenism and pregnancy rate.<\/jats:p>","DOI":"10.33549\/physiolres.933266","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T08:49:35Z","timestamp":1582879775000},"page":"815-822","source":"Crossref","is-referenced-by-count":16,"title":["The Effect of Alfacalcidiol and Metformin on Phenotype Manifestations in Women with Polycystic Ovary Syndrome \u2013 a Preliminary Study"],"prefix":"10.33549","author":[{"given":"I.","family":"DRAVECK\u00c1","sequence":"first","affiliation":[{"name":"First Department of Internal medicine, Medical faculty of P. J. \u0160afarik University, Ko\u0161ice, Slovakia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"FIGUROV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"JAVORSK\u00dd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"PETR\u00cdKOV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"VA\u013dKOV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"LAZ\u00daROV\u00c1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2016,10,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"ARDABILI HR, GARGARI BP, FARZADI L: Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res 32: 195-201, 2012.","DOI":"10.1016\/j.nutres.2012.02.001"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"AZZIZ R, CARMINA E, DEWAILLY D, DIAMANTI-KANDARAKIS E, ESCOBAR-MORREALE HF, FUTTERWEIT W, JANSSEN OE, LEGRO RS, NORMAN RJ, TAYLOR AE, WITCHEL SF: Position statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society Guideline. J Clin Endoc Metab 91: 4237-4245, 2006.","DOI":"10.1210\/jc.2006-0178"},{"key":"ref2","unstructured":"BONAKDARAN S, MAZLOOM KHORASANI Z, DAVACHI B, MAZLOOM KHORASANI J: The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial. Iran J Reprod Med 10: 465-472, 2012."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"BOUILLON R, VAN SCHOOR NM, GIELEN E, BOONEN S, MATHIEU C, VANDERSCHUEREN D, LIPS P: Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. Clin Endocrinol Metab 98: 1283-1304, 2013.","DOI":"10.1210\/jc.2013-1195"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"DIAMANTI-KANDARAKIS E, DUNAIF A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33: 981-1030, 2012.","DOI":"10.1210\/er.2011-1034"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"FIGUROV\u00c1 J, DRAVECK\u00c1 I, JAVORSK\u00dd M, PETR\u00cdKOV\u00c1 J, LAZUROV\u00c1 I: The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. Horm Mol Biol Clin Investig, in press 2016.","DOI":"10.1515\/hmbci-2016-0039"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"FIGUROV\u00c1 J, DRAVECK\u00c1 I, JAVORSK\u00dd M, PETR\u00cdKOV\u00c1 J, LAZUROV\u00c1 I: Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities. Wien Klin Wochenschr 2015. DOI: 10.1007\/s00508-015-0768-9.","DOI":"10.1530\/endoabs.37.ep164"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"FIROUZABADI RD, AFLATOONIAN A, MODARESSI S, SEKHAVAT L, MOHAMMAD TAHERI S: Therapeutic effects of calcium and vitamin D supplementation in women with PCOS. Complement Ther Clin Pract 18: 85-88, 2012.","DOI":"10.1016\/j.ctcp.2012.01.005"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"HAHN S, HASELHORST U, TAN S, QUADBECK B, SCHMIDT M, ROESLER S, KIMMIG R, MANN K, JANSSEN OE: Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 114: 577-583, 2006.","DOI":"10.1055\/s-2006-948308"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"KOTSA K, YAVROPOULOU MP, ANASTASIOU O, YOVOS JG: Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril 92: 1053-1058, 2009.","DOI":"10.1016\/j.fertnstert.2008.07.1757"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"LI HWR, BRERETON RE, ANDERSON RA, WALLACE AM, HO CK: Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 60: 1475-1481, 2011.","DOI":"10.1016\/j.metabol.2011.03.002"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"MARCH WA, MOORE VM, WILLSEN KJ, PHILLIPS DI, NORMAN RJ, DAVIES MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25: 544-551, 2010.","DOI":"10.1093\/humrep\/dep399"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"RASHIDI B, HAGHOLLAHI F, SHARIAT M, ZAYERII F: The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol 48: 142-147, 2009.","DOI":"10.1016\/s1028-4559(09)60275-8"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"SELIMOGLU H, DURAN C, KIYICI S, ERSOY C, GUCLU M, OZKAYA G, TUNCEL E, ERTURK E, IMAMOGLU S: The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest 33: 234-238, 2010.","DOI":"10.1007\/bf03345785"},{"key":"ref14","unstructured":"TEHRANI HG, MOSTAJERAN F, SHAHSAVARI S: The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrognism state of women with polycystic ovarian syndrom. J Res Med Sci 19: 875-880, 2014."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"THYS-JACOBS S, DONOVAN D, PAPADOPOULOS A, SARREL P, BILEZIKIAN JP: Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 64: 430-535, 1999.","DOI":"10.1016\/s0039-128x(99)00012-4"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"WEHR E, PILZ S, SCHWEIGHOFER N, GIULIANI A, KOPERA D, PIEBER TR, OBERMAYER-PIETSCH B: Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 161: 575-582, 2009.","DOI":"10.1530\/eje-09-0432"},{"key":"ref17","unstructured":"WEHR E, PIEBER TR, OBERMAYER- PIETSCH B: Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest 34: 757-763, 2011."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"YILDIZHAN R, KURDOGLU M, ADALI E, KOLUSARI A, YILDIZHAN B, SAHIN HG, KAMACI M: Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 280: 559-563, 2009.","DOI":"10.1007\/s00404-009-0958-7"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T08:49:38Z","timestamp":1582879778000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomed.cas.cz\/physiolres\/pdf\/65\/65_815.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,15]]},"references-count":19,"URL":"https:\/\/doi.org\/10.33549\/physiolres.933266","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10,15]]}}}